Immix Biopharma, Inc. IMMX Deferred contract costs
Deferred contract costs at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredCosts.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s deferred contract costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s deferred contract costs?
- Immix Biopharma, Inc. (IMMX) reported deferred contract costs of $164.72K in Q1 2026.
- What is the long-term trend for Immix Biopharma, Inc.'s deferred contract costs?
- Over 2 years (2022 to 2025), Immix Biopharma, Inc.'s deferred contract costs has grown at a 273.2% compound annual growth rate (CAGR), from $6.72K to $93.63K.
- What does deferred contract costs mean?
- These are incremental costs incurred to obtain a contract that are expected to be recovered over a period longer than one year. This asset reflects the capitalization of costs that would otherwise have been expensed, aligning the recognition of expenses with the related revenue streams. It is a key indicator of long-term contract acquisition efficiency.